Clinical Development of <i>Senza5TM CART5:</i> a Novel Dual Population CD5 CRISPR-Cas9 Knocked out Anti-CD5 Chimeric Antigen Receptor T Cell Product for Relapsed and Refractory CD5+ Nodal T-Cell Lymphomas
Ruchi P. Patel(University of Pennsylvania), Marco Ruella(Parker Institute for Cancer Immunotherapy), Dean Qian(Oncoceutics (United States)), Guido Ghilardi(Hospital of the University of Pennsylvania), Nicholas A. Siciliano(Oncoceutics (United States)), Patrizia Porazzi(Hospital of the University of Pennsylvania), Adam E. Snook(Thomas Jefferson University), Stephen J. Schuster(Hospital of the University of Pennsylvania), Aditya Nimmagadda(Oncoceutics (United States)), Raymone Pajarillo(Hospital of the University of Pennsylvania), Michael Wang(St. Joseph Health System), Yunlin Zhang(Hospital of the University of Pennsylvania), Steven Yang(Oncoceutics (United States)), Stefan K. Barta(University of Pennsylvania)
Cited by 8
Related Papers
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
|JAMA Oncology|2019|829
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
|Journal of Clinical Investigation|2016|554
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523
Diffuse large B‐cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment
|American Journal of Hematology|2019|503